ABSTRACT

Background Patients often report persistent symptoms beyond the acute infectious phase of COVID-19. Hyperpolarised $^{129}$Xe MRI provides a way to directly measure airway functional abnormalities; the clinical relevance of $^{129}$Xe MRI ventilation defects in ever-hospitalised and never-hospitalised people with post-acute COVID-19 syndrome. BMJ Open Resp Res 2022:9:e001235. doi:10.1136/bmjresp-2022-001235

Methods Consenting participants with a confirmed diagnosis of PACS completed $^{129}$Xe MRI, CT, spirometry, multi-breath inert-gas washout, 6-minute walk test, St. George’s Respiratory Questionnaire (SGRO), modified Medical Research Council (mMRC) dyspnoea scale, modified Borg scale and International Physical Activity Questionnaire. Consent ing ever-COVID volunteers completed $^{129}$Xe MRI and pulmonary function tests only.

Results Seventy-six post-COVID and nine never-COVID participants were evaluated. Ventilation defect per cent (VDP) was abnormal and significantly greater in ever-COVID as compared with never-COVID participants ($p<0.001$) and significantly greater in ever-hospitalised compared with never-hospitalised participants who had COVID-19 ($p=0.048$), in whom diffusing capacity of the lung for carbon-monoxide ($D_{LCO}$) was $0.009$ and 6-minute walk distance (6MWD) ($p=0.005$) were also significantly different. $^{129}$Xe MRI VDP was also related to the 6MWD ($p=0.02$) and post-exertional $SpO_2$ ($p=0.002$). Participants with abnormal VDP ($>4.3\%$) had significantly worse 6MWD ($p=0.003$) and post-exertional $SpO_2$ ($p=0.03$).

Conclusion $^{129}$Xe MRI VDP was significantly worse in ever-hospitalised as compared with never-hospitalised participants and was related to 6MWD and exertional $SpO_2$ but not SGRQ or mMRC scores.

Trial registration number NCT05014516.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Some patients report persistent symptoms and exercise limitation beyond the acute infectious phase of COVID-19. It remains unclear if such symptoms are related to ventilation heterogeneity and airways disease.

WHAT THIS STUDY ADDS

⇒ We measured $^{129}$Xe MRI ventilation defects, pulmonary function, quality-of-life and exercise capacity in ever-hospitalised and never-hospitalised patients who had COVID-19 with persistent symptoms consistent with post-acute COVID-19 syndrome. $^{129}$Xe MRI ventilation defect per cent (VDP) was significantly worse in ever-COVID as compared with never-COVID participants and also worse in ever-hospitalised as compared with never-hospitalised participants. MRI VDP was related to the 6-minute walk distance and post-exertional $SpO_2$ but not quality-of-life scores.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ MRI VDP, which itself has been shown to reflect airway abnormalities, was abnormal in ever-hospitalised and never-hospitalised patients who had COVID-19 and related to post-exertional $SpO_2$ and exercise limitation. These data contribute to the growing body of evidence that post-acute COVID-19 has an airways disease component which may be considered for treatment.

INTRODUCTION

Long-term symptoms and poor quality-of-life beyond the acute infectious phase of coronavirus disease 2019 (COVID-19) has been reported in a wide range of 14%–89% of infected people. This has been described as having long-COVID, post-acute...
COVID-19 syndrome (PACS) and post-acute sequelae of COVID-19. It is perhaps not surprising that some patients who had COVID-19 who were hospitalised to manage severe illness also experience reduced quality-of-life, poor pulmonary function and pulmonary imaging abnormalities well after the infection is resolved. However, many patients who experienced milder symptoms and were managed at home also experience long-term symptoms. Regardless, the aetiology of long-term symptoms is not yet well understood, which stymies treatment options.

CT imaging has provided the mainstay imaging approach for COVID-19 diagnosis and monitoring in the infectious and post-infectious phase. While some patients experience complete radiological resolution in the months following COVID-19 infection, CT fibrosis-like changes, ground-glass opacities and interstitial thickening have been reported to persist in 35%–72% of patients. Until now, quantitative CT analysis of patients who are post-COVID has been limited to density metrics; airway measurements have not yet been examined.

Hyperpolarised noble gas MRI provides a way to quantify the functional consequences of airway obstruction via inhaled gas distribution abnormalities or ventilation defects. Previously, single-centre 129Xe MRI investigations reported abnormal gas-exchange and mildly abnormal ventilation defect percentage in previously hospitalised patients evaluated 14–254 days post discharge. MRI ventilation defects were previously shown to reflect airway inflammation and remodeling, relate to dyspnoea and disease severity, predict the transition of reversible asthma to irreversible chronic obstructive pulmonary disease (COPD), and uniquely explain asthma control scores and COPD exacerbations.

Our objective was to evaluate symptomatic ever-COVID patients, including never-hospitalised and ever-hospitalised participants, who were experiencing post-COVID symptoms months after a positive COVID-19 test. We hypothesised that ventilation defect percent (VDP) would be significantly greater in ever-hospitalised as compared with never-hospitalised COVID-19 participants and VDP would be significantly related to quality-of-life and symptoms.

**METHODS**

**Participant and public involvement**

The development of the research question and outcome measures did not involve potential participants. Results for each individual participant were provided to them directly and also provided to a member of their healthcare team, if requested by the participant. Overall results were disseminated to all study participants at follow-up visits and the manuscript will be shared widely with all participants, once peer-reviewed and accepted for publication.

**Study participants and design**

Participants were enrolled from two clinical research centres (Site 1: Robarts Research Institute, London, Canada; Site 2: St Joseph’s Healthcare Hamilton, Hamilton, Canada) and Health Canada approved and published protocols (www.clinicaltrials.gov). Participants were recruited from a local quaternary care post-COVID-19 clinic at Site 1 and through referral from healthcare providers or self-referral through advertising at Site 2. Inclusion criteria for Site 1 consisted of individuals aged 18–80 years, a local public health office confirmed (positive-test) case of COVID-19, persistent symptoms up to 3 months post infection, including but not limited to respiratory, neurological and metabolic systems, and a clinical diagnosis of PACS. Inclusion criteria for Site 2 consisted of people aged 18 or older who recently (<12 weeks) recovered from COVID-19 with the date of recovery confirmed in accordance with provincial and local public health unit protocols. All participants in this analysis reported post-COVID symptoms at the time of their research visit.

Never-COVID controls were recruited by local advertisement; research visits were completed during the period June–July 2021, prior to the participant’s full vaccination. All never-COVID controls were recruited on the basis of a negative history for chronic cardiorespiratory illness and symptomatic respiratory illness during the period February 2020 up to and including the study visit. A subset of ever-COVID (n=17) and never-COVID (n=6) participants evaluated here were previously evaluated for gas-exchange MRI abnormalities (Matheson et al Persistent Lung Vascular Abnormalities in Never-hospitalized people with post-acute COVID-19 syndrome. Under review). Ever-COVID participants at both sites completed spirometry, diffusing capacity of the lung for carbon monoxide (DLCO), 1H and 129Xe ventilation MR and CT imaging in addition to the St. George’s Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC) dyspnoea scale, modified Borg scale, International Physical Activity Questionnaire (IPAQ), and 6-minute walk test. ever-COVID participants at Site 1 also completed multi-breath inert gas washout. Never-COVID volunteers were evaluated using vital signs, spirometry, multi-breath inert gas washout and 1H and 129Xe ventilation MRI.

**Pulmonary function tests and questionnaires**

Participants performed spirometry for the forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) according to American Thoracic Society guidelines using the EasyOne Pro LAB system (ndd Medical Technologies, Zurich, Switzerland) at Site 1 and using the Elite DX plethysmograph (MedGraphics Corporation, St. Paul, Minnesota, USA) and/or CPFS/D USB Spirometer (MedGraphics Corporation) at Site 2. Multi-breath inert gas washout, also performed using the EasyOne Pro LAB system equipped with an ultrasonic
flow and molar mass sensor, measured the lung clear-
ance index (LCI) at Site 1.\textsuperscript{33} $D_{1-cw}$ was also measured
using the EasyOne Pro LAB system at Site 1 and the
Elite DX plethysmograph at Site 2, according to Euro-
pean Respiratory Society guidelines.\textsuperscript{34} In addition,
SQRQ, mMRC, modified Borg scale, IPAQ and 6-minute
walk test were self-administered under the supervision
of study personnel.

Thoracic imaging
Anatomic \textsuperscript{3}H and \textsuperscript{129}Xe static ventilation MRI were
acquired at both sites using 3.0 Tesla scanners (Discovery
MR750; GE Healthcare, Milwaukee, USA), as previously
described.\textsuperscript{35} \textsuperscript{129}Xe ventilation MRI was acquired using a
flexible vest coil (Clinical MR Solutions, Site 1) or
asymmetric quadrature bird cage coil (custom built;
Site 2).\textsuperscript{36} Supine participants were coached to inhale a
1.0 L bag (Teldar; Jensen Inert Products, Coral Springs,
Florida, USA) (400 mL, \textsuperscript{129}Xe+600 mL \textsuperscript{3}He at Site 1 or
600 mL \textsuperscript{129}Xe+400 mL \textsuperscript{3}He at Site 2 and 1.0 L \textsuperscript{3}He,
for \textsuperscript{3}H MRI) from the bottom of a tidal breath (functional
residual capacity) with acquisition under breath-hold
conditions.\textsuperscript{37} \textsuperscript{129}Xe gas was polarised to 8%–40% (Site 1:
Xenispin 9820, Site 2: Xenispin 9800; Polarean, Durham,
North Carolina, USA).\textsuperscript{38}

Within 30 min of MRI, CT was acquired as previously
described\textsuperscript{39} (Site 1: 64-slice LightSpeed VCT system, GE
Healthcare, Milwaukee, Wisconsin, USA; Site 2: Discovery
MI PET/CT scanner, GE Healthcare).

Image analysis
Anonymised MRI data sets were transferred from Site
2 to Site 1 for analysis using a cloud-based institutional
server and were evaluated in a random order. Quantita-
tive VDP analysis was performed with data anonymised
as previously described\textsuperscript{40} by a single expert observer (MJM)
using a semi-automated segmentation software pipeline
\textsuperscript{41} generated in Matlab 2019a (Mathworks, Natick,
Massachusetts, USA). VDP was generated by normalising
ventilation defect volume to the \textsuperscript{3}H MRI thoracic cavity
volume, as previously described.\textsuperscript{42} Abnormal VDP was
defined as the upper limit of normal (95% CI), previously
described\textsuperscript{43} for \textsuperscript{3}He MRI; since \textsuperscript{129}Xe MRI VDP is more
sensitive to ventilation abnormalities as compared with
\textsuperscript{3}He MRI VDP,\textsuperscript{44} this provides a conservative estimate.

CT images were analysed by a single expert (HKK)
using VIDAvision software (VIDA Diagnostics, Coralville,
Iowa, USA) to generate total airway count (TAC).\textsuperscript{45}
Anatomically equivalent segmental, subsegmental and
sub-subsegmental airways for all airways paths (third
to fifth generation) were also used to generate airway
lumen area, wall area and wall thickness measurements.\textsuperscript{46}
CT images were also evaluated by two experienced chest
radiologists (MA, Site 1 and EAH, Site 2).

Endpoints and statistical analysis
The primary endpoints were: (1) \textsuperscript{129}Xe MRI VDP differ-
ences between ever-hospitalised and never-hospitalised
COVID-19 participants, and, (2) \textsuperscript{129}Xe MRI VDP rela-
tionships with quality-of-life and exercise limitation.
Secondary endpoints included the relationship for
\textsuperscript{129}Xe MRI VDP with CT airway measurements and with
pulmonary function, and differences in quality-of-life and
6-minute walk distance (6MWD) in ever-COVID
participants with and without abnormal VDP ≥4.3%.\textsuperscript{41}
An exploratory endpoint was the analysis of VDP in ever-
COVID participants with and without a prior history of
chronic respiratory illness.

SPSS (SPSS Statistics V.25.0; IBM, Armonk, New York,
USA) was used for all statistical analyses. Data were tested
for normality using Shapiro-Wilk tests and non-parametric
tests were performed when data were not normally
distributed. Differences between subgroups were evalu-
ated using independent samples t-tests and analysis of
variance. Univariate relationships were evaluated using
Pearson (r) correlations for normally distributed vari-
bles and Spearman (ρ) correlations for non-normally
distributed variables. The Holm-Bonferroni correction
was used for multiple comparisons in univariate analy-
ses. Results were considered statistically significant when
the probability of making a type I error was less than 5%
(p<0.05).

RESULTS
Participants
A CONSORT (Consolidated Standards of Reporting
Trials) diagram provided in figure 1 shows that from
August 2020 to September 2021, 93 participants were
enrolled (68 from Site 1 and 25 from Site 2), including 80
ever COVID and 13 never COVID volunteers. Four never-
COVID participants were excluded due to inflammatory
disease (rheumatoid arthritis, asthma), hypertensive crisis
and the detection of a large asymptomatic atrial septal
defect.\textsuperscript{44} Four COVID-19 participants could not undergo
MRI and were also excluded from the analysis. In total,
9 never COVID participants (five women and four men;
mean age 36±12 year) and 76 ever COVID participants
(38 women and 38 men; mean age 53±12 year) were evalu-
at. COVID-19 participants were evaluated 13.8±8.5
weeks following a positive COVID-19 test.

Table 1 provides a summary of baseline characteris-
tics for 9 never COVID and 76 ever COVID participants
including 23 (30%) ever-hospitalised and 53 (70%)
never-hospitalised participants. There were significant
differences for age (p<0.001) and sex (p=0.001) between
participant subgroups. Of the 23 hospitalised partici-
ants, 3 required mechanical ventilation, 1 required non-
invasive ventilation and 18 were provided supplemental
oxygen during their hospital admission. Online supple-
mental table S1 provides baseline demographics by site
and shows that the number of weeks between a positive
COVID-19 test and the research visit (p=0.01), as well as

Kooner HK, et al. BMJ Open Resp Res 2022;9:e001235. doi:10.1136/bmjresp-2022-001235

Open access

BMJ Open Resp Res: first published as 10.1136/bmjresp-2022-001235 on 18 May 2022. Downloaded from http://bmjopenresp.bmj.com/ on December 1, 2022 by guest. Protected by copyright.
SpO₂ (p=0.01) were significantly different between the two sites. Online supplemental table S2 provides a by-participant list of current medications and online supplemental table S3 provides a summary of these medications.

### Imaging and other endpoints

Figure 2 shows representative ¹²⁹Xe ventilation MRI (cyan) co-registered with anatomical ¹H MRI (greyscale) for three never-COVID and four ever-COVID participants, for which there is also representative coronal CT and segmented airway trees. For never-COVID volunteers, there was visually obvious homogeneous ventilation and VDP was <1% (P77 VDP=0.9%, P78 VDP=0.7%, P79 VDP=0.6%). For ever-COVID participants, there was visually obvious ventilation heterogeneity or defects and yellow arrows point to regions of interest with ventilation

### Table 1 Demographic characteristics

| Parameter                                      | Never-COVID (n=9) | All COVID participants | Ever hospitalised (n=23) | Never hospitalised (n=53) | Sig. p value |
|------------------------------------------------|-------------------|------------------------|--------------------------|---------------------------|--------------|
| Age, years                                     | 36 (12)           | 53 (12)                | 57 (13)                  | 52 (12)                   | <0.001       |
| Female, n (%)                                  | 5 (56)            | 38 (50)                | 5 (22)                   | 33 (62)                   | 0.001        |
| BMI, kg/m²                                      | 26 (5)            | 30 (5)                 | 31 (5)                   | 29 (6)                    | 0.07         |
| SpO₂, %                                        | 97 (2)*           | 97 (2)                 | 97 (2)                   | 97 (2)                    | 0.4          |
| Heart rate, beats/min                          | 87 (20)*          | 77 (13)                | 82 (14)                  | 76 (12)                   | 0.05         |
| Blood pressure, mm Hg                          | 118/79 (18/12)*   | 125/81 (14/10)         | 124/81 (15/11)           | 124/81 (15/9)             | –            |
| Weeks since positive COVID-19 test (mean/median: min–max) | N/A               | (13.8/12.0: 5.0–53.4)  | (15.2/12.0: 5.0–53.4)    | (13.2/12.0: 5.0–39.6)     | 0.3          |
| Smoking history, pack-years                    | 0 (0)             | 8 (18)                 | 10 (21)                  | 8 (16)                    | 0.3          |
| No prior respiratory illness, n (%)           | 9 (100)           | 49 (64)                | 16 (70)                  | 33 (62)                   | 0.5          |
| Prior respiratory illness, n (%)              | 0 (0)             | 27 (36)                | 7 (30)                   | 20 (38)                   | 0.5          |
| Asthma, n (%)                                  | 0 (0)             | 21 (26)                | 5 (22)                   | 16 (30)                   | 0.4          |
| COPD, n (%)                                    | 0 (0)             | 6 (8)                  | 2 (9)                    | 4 (8)                     | 0.9          |
| Hospital admission days                        | N/A               | 13 (16)                | 13 (16)                  | N/A                       | –            |

Age and the proportion of women is significantly different between groups. Values are reported as mean (SD) unless otherwise indicated. p=significance value for analysis of variance between never-COVID, ever-hospitalised and never-hospitalised. *n=6.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; SpO₂, pulse oximetry estimation of arterial blood oxygen saturation made on a fingertip.
Figure 2  Representative $^{129}$Xe MRI Ventilation and CT airways. (A) Centre coronal $^{129}$Xe MRI slice (cyan) co-registered with $^1$H MRI thoracic cavity (greyscale) in three never-COVID participants (P77: female, VDP=0.9%; P78: female, VDP=0.7%; P79: female, VDP=0.6%). (B) Two coronal $^{129}$Xe MRI slices (cyan) co-registered with $^1$H MRI thoracic cavity (greyscale) and CT with segmented airway tree in four ever-COVID participants. Yellow arrows point to MRI or CT abnormalities. P26 was a male with no prior respiratory illness and FEV$_1$=95%, LCI=8.9, SGRQ=36, mMRC=1, VDP=4.2% and TAC=475. P53 was a male with no prior respiratory illness and FEV$_1$=87%, LCI=8.2, SGRQ=51, mMRC=1, VDP=2.8% and TAC=301. P14 was a female with asthma and never-hospitalised, FEV$_1$=71%, SGRQ=37, mMRC=0, VDP=17.7% and TAC=289. P02 was a male with COPD and ever-hospitalised, FEV$_1$=96%, LCI=8.0, SGRQ=14, mMRC=0, VDP=8.0% and TAC=169. COPD, chronic obstructive pulmonary disease; FEV$_1$, forced expiratory volume in 1 s; LCI, lung clearance index; mMRC, modified Medical Research Council; SGRQ, St. George’s Respiratory Questionnaire; TAC, total airway count; VDP, ventilation defect per cent.
or CT abnormalities. In participant P26, there was a large ventilation defect in the right upper lobe that spatially corresponded to a radiodense region visible on CT. In participant P53, there were ventilation defects in the periphery of the upper lobes. In participants P14 and P02, there were large ventilation defects in the lung periphery. Online supplemental table S4 shows CT diagnostic findings, for a subset of participants with CT reports completed by a radiologist, including ground-glass opacities (20/50, 40%), atelectasis (14/50, 28%), nodules (13/50, 26%) and bronchiectasis (11/50, 22%).

These qualitative findings are reflected in the quantitative findings shown in table 2 which summarises pulmonary function test, imaging and questionnaire data. Online supplemental table S5 shows all pulmonary function test, imaging and questionnaire data by site, while online supplemental table S6 and figure S1 show these findings by previously diagnosed asthma and COPD.

As shown in table 2, there were significant differences among subgroups for FEV₁ (p=0.005), FVC (p=0.004), LCI airway opening (LCIₐₒ) (p=0.04), DLCO (p=0.009), 6MWD (p=0.005), post-exertional SpO₂ (p=0.03) and SpO₂ post-exertion (p=0.03). Values are reported as mean (SD) unless otherwise indicated.

### Table 2: Pulmonary function, questionnaire and imaging measurements

| Parameter                         | Never-COVID (n=9) | Ever-COVID (n=76) | Ever hospitalised (n=23) | Never hospitalised (n=53) | Sig. p value |
|-----------------------------------|-------------------|-------------------|--------------------------|---------------------------|--------------|
| **Pulmonary function**            |                   |                   |                          |                           |              |
| FEV₁*%/pred                       | 101 (11)          | 85 (20)           | 77 (21)                  | 88 (19)                   | 0.005        |
| FVC*%/pred                        | 103 (10)          | 88 (20)           | 80 (18)                  | 92 (20)                   | 0.004        |
| FEV₁/FVC*                         | 0.81 (0.04)       | 0.76 (0.11)       | 0.75 (0.14)              | 0.77 (0.09)               | 0.3          |
| LCI* n breaths                    | 9.0 (1.4)         | 10.7 (3.9)        | 11.8 (5.0)               | 10.1 (3.0)                | 0.2          |
| LCIₐₒ* n breaths                  | 8.0 (1.3)         | 9.5 (3.3)         | 11.4 (4.9)               | 8.6 (1.8)                 | 0.04         |
| DLCO*%/pred                       | –                 | 89 (29)           | 75 (23)                  | 95 (29)                   | 0.009        |
| **Exercise capacity and QoL**     |                   |                   |                          |                           |              |
| 6MWD* m                           | –                 | 454 (84)          | 405 (86)                 | 471 (76)                  | 0.005        |
| SpO₂ post-exertion* %             | –                 | 97 (3)            | 95 (5)                   | 98 (2)                    | 0.03         |
| SGRQ*                             | –                 | 35 (18)           | 37 (15)                  | 34 (19)                   | 0.6          |
| mMRC*                             | –                 | 1 (1)             | 1 (1)                    | 1 (1)                     | 0.6          |
| IPAQ* MET-minutes                 | –                 | 4709 (4895)       | 3048 (3433)              | 5327 (5238)               | 0.1          |
| **MRI**                           |                   |                   |                          |                           |              |
| VDP %                             | 1.1 (0.9)         | 5.4 (7.1)         | 7.8 (11.1)               | 4.4 (4.2)                 | 0.03         |
| TAC                               | 270 (110)         | 294 (175)         | 263 (88)                 | 0.5                       |
| WA mm²                            | 66 (2)            | 66 (2)            | 66 (2)                   | 0.4                       |
| LA mm²                            | 14 (3)            | 15 (4)            | 14 (3)                   | 0.5                       |
| WT mm                             | 1.4 (0.1)         | 1.4 (0.1)         | 1.4 (0.1)                | 0.7                       |

FEV₁, FVC, LCIₐₒ, DLCO, 6MWD, SpO₂, post-exertion and VDP significantly differ between groups. Values are reported as mean (SD) unless otherwise indicated. p=significance value for analysis of variance between never-COVID, ever-hospitalised and never-hospitalised. FEV₁*, FVC*, FEV₁/FVC*: Never-hospitalised n=52. LCI*: Never-COVID n=5, Ever-COVID n=44, Ever-hospitalised n=16, Never-hospitalised n=28. LCIₐₒ*: Never-COVID n=5, Ever-COVID n=32, Ever-hospitalised n=10, Never-hospitalised n=22. DLCO*: Ever-COVID n=64, Ever-hospitalised n=20, Never-hospitalised n=44. 6MWD* and mMRC*: Ever-COVID n=66, Ever-hospitalised n=17, Never-hospitalised n=49. SpO₂ post-exertion*: Ever-COVID n=65, Ever-hospitalised n=17, Never-hospitalised n=49. SGRQ*: Ever-COVID n=64, Ever-hospitalised n=16, Never-hospitalised n=48. IPAQ*: Ever-COVID n=59, Ever-hospitalised n=16, Never-hospitalised n=43. CT*: Ever-COVID n=56 with 44 amenable to quantitative analysis, Ever-hospitalised n=9, Never-hospitalised n=35. ao, airway opening; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; IPAQ, International Physical Activity Questionnaire; LA, lumen area; LCI, lung clearance index; MET, metabolic equivalent; mMRC, modified Medical Research Council dyspnea score; 6MWD, 6-minute walk distance; %pred, percent of predicted value; QoL, quality-of-life; SGRQ, St. George's Respiratory Questionnaire; SpO₂, pulse oximetry estimation of arterial blood oxygen saturation made on a fingertip; TAC, total airway count; VDP, ventilation deficit percent; WA, wall area; WT, wall thickness.
129Xe MRI VDP (p=0.03). In addition, mean VDP (≥4.3%), 43 SGRQ (≥6) 45 and LCI/LCI, (≥7.5) 46 were abnormal in ever-COVID as well as the ever-hospitalised and never-hospitalised participant subgroups.

Box and whisker plots in figure 3 show that 129Xe MRI VDP was significantly greater in ever-COVID as compared with never-COVID (p=0.048) and never-COVID (p=0.01), 6MWD significantly different for ever-hospitalised versus never-hospitalised (p=0.005). DLCO significantly different for ever-hospitalised versus never-hospitalised (p=0.009). LCI, IPAQ and SGRQ not significantly different. DLCO, diffusing capacity of the lung for carbon-monoxide; IPAQ, International Physical Activity Questionnaire; LCI, lung clearance index; SGRQ, St. George’s Respiratory Questionnaire; VDP, ventilation defect per cent; 6MWD, 6-minute walk distance; % pred, per cent of predicted value.

129Xe MRI VDP (p=0.03). In addition, mean VDP (≥4.3%), 43 SGRQ (≥6) 45 and LCI/LCI, (≥7.5) 46 were abnormal in ever-COVID as well as the ever-hospitalised and never-hospitalised participant subgroups.

Box and whisker plots in figure 3 show that 129Xe MRI VDP was significantly greater in ever-COVID as compared with never-COVID (p=0.001), and in ever-hospitalised as compared with never-COVID (p=0.01). 6MWD significantly different for ever-hospitalised versus never-hospitalised (p=0.005). DLCO significantly different for ever-hospitalised versus never-hospitalised (p=0.009). LCI, IPAQ and SGRQ not significantly different. DLCO, diffusing capacity of the lung for carbon-monoxide; IPAQ, International Physical Activity Questionnaire; LCI, lung clearance index; SGRQ, St. George’s Respiratory Questionnaire; VDP, ventilation defect per cent; 6MWD, 6-minute walk distance; % pred, per cent of predicted value.

Relationships
Figure 4 shows linear relationships for imaging and pulmonary function measurements. For completeness and transparency, online supplemental table S7 provides the Pearson or Spearman correlations for all parameters measured. As shown in figure 4, there were significant respiratory diagnosis (p<0.001). The 6MWD was also significantly worse (p=0.02) in participants with prior COPD as compared with those with no prior respiratory diagnosis. Participants were dichotomised by VDP (normal VDP <4.3%, total n=49, hospitalised n=15; abnormal VDP ≥4.3%, total n=27, hospitalised n=8). As shown in online supplemental figure S2, participants with abnormal VDP also had significantly worse 6MWD (p=0.003) and post-exertional \( \text{SpO}_2 \) (p=0.03).
relationships for VDP with 6MWD ($\rho=-0.31; p=0.02$) and post-exertional $\text{SpO}_2$ ($\rho=-0.43; p=0.002$) and for post-exertional $\text{SpO}_2$ with LCI ($\rho=-0.49; p=0.01$). CT measurement relationships included TAC with FEV$_1$/FVC ($\rho=0.30$, $p=0.03$), CT wall thickness with FEV$_1$ ($r=0.30$, $p=0.046$) and CT wall area with FEV$_1$/FVC ($\rho=-0.35$, $p=0.04$).

DISCUSSION
To our knowledge, this is the first multicentre study that explores ventilation heterogeneity in ever-hospitalised and never-hospitalised post-COVID-19 participants with persistent and serious symptoms necessitating clinical follow-up. In 76 participants, we observed: (1) significantly different (worse) MRI VDP in ever-COVID as compared with never-COVID, and in never-hospitalised as compared with ever-hospitalised COVID-19 participants, who also experienced significantly different (worse) DL$_{CO}$ and 6MWD, (2) significant relationships between CT airway and spirometry measurements and (3) significant relationships between post-exertional $\text{SpO}_2$ with two measurements of ventilation heterogeneity, MRI VDP and LCI, and between MRI VDP and the 6MWD.

First, we observed that MRI VDP was significantly different in ever-COVID as compared with never-COVID participants and mean VDP in ever-COVID patients was consistent with previously reported values$^{20}$ in asymptomatic ever-hospitalised patients, post discharge. The finding of significantly different MRI VDP in ever-hospitalised as compared with never-hospitalised participants was novel as was the coincident finding of significantly different 6MWD and post-exertional $\text{SpO}_2$ in these participants. Previous studies have observed worse 6MWD in severe versus mild–moderate post-COVID patients, however, the classification for mild, moderate or severe infection was not based on prior hospitalisation and not all participants experienced ongoing COVID-19 symptoms. When dichotomised by VDP, 6MWD and post-exertional $\text{SpO}_2$ were also significantly different between groups. The link between exercise limitation, post-exertional oxygen saturation and ventilation heterogeneity in PACS is novel and points to a mechanistic relationship between persistent symptoms and airway pathologies and/or occlusion/obliteration.

Underscoring these central results was the finding of significant relationships for post-6MWD $\text{SpO}_2$ with MRI VDP and with LCI—both are measurements of ventilation heterogeneity that are thought to reflect airway inhalational (MRI) and exhalational (LCI) function. This is the first supportive evidence of a potential link between exercise intolerance following COVID-19 and objective (LCI and MRI VDP) and direct (MRI VDP) measurements of abnormal airway function. This evidence was also supported by the significant associations between CT findings including total airway count (reflecting airway narrowing or obliteration/occlusion), airway lumen area (narrowing or occlusion) and airway wall thickness with spirometry measurements of airflow obstruction. Recent studies have provided evidence of small airways disease in post-COVID-19 patients using the full-scale airway network flow model$^{23}$ or CT air-trapping functional small airways disease.$^{31}$ We did not acquire inspiratory–expiratory CT and thus could not quantify CT air-trapping, although the ratio of residual volume to total lung capacity (RV/TLC) was measured in 38 of our 76 participants and of these, 14 (37%) reported RV/TLC > upper limit of normal.$^{32}$ In addition, the median RV/TLC value in these 38 participants was 0.41±0.17, suggesting air-trapping, and this value was greater than the evaluation group reported by Cho et al (median RV/TLC=0.30).$^{31}$ Taken together, these findings support the use of airways disease treatments, including inhaled combination corticosteroid–long-acting beta agonist, in post-COVID patients with persistent symptoms.

We acknowledge a number of limitations in this convenience-sample study, including the relatively small sample size. We should note that Site 1 participants were monitored over time by a long-COVID clinic designed to follow and treat long-term symptoms, including dyspnoea, and this clinic referred participants to consider enrolling in the study. Hence, there is a potential for bias towards a greater number and intensity of unexplained symptoms for participants enrolled. In addition, for most of the never-hospitalised participants enrolled, there was no prior clinical history of respiratory disease and thus first-time chest imaging and pulmonary function test results were reported. Therefore, we had to untangle any previous clinical history from the impact of COVID-19 on symptoms. Furthermore, pulmonary function tests, as well as CT and MR imaging measurements, prior to COVID-19 infection were not available, and thus, the impact of COVID-19 on existing lung function is still not completely clear. For a relatively large number of ever-COVID participants, chest CT was either declined (n=18) or not quantitatively evaluable (n=13) which also limits the generalisability of the CT results. It is also important to acknowledge that this was a multicentre study, with participants enrolled from two relatively diverse regional healthcare systems embedded within a population of 14.7 million people served by a single universal and comprehensive healthcare insurance plan. Site 1 enrolment derived from a quaternary care academic health centre serving a mainly rural population and Site 2 enrolment derived from another quaternary care academic health centre, located about 100 km away from Site 1 with a mainly urban population, hence our findings may not be generalisable to other healthcare jurisdictions. Moreover, we also recognise that the convenience study group we evaluated included a relatively large number of people with previously diagnosed asthma (n=21) and COPD (n=6), which is a greater proportion of patients with comorbid obstructive lung disease than previous reports.$^{2,5,19}$ We expect that the presence of previous obstructive lung disease likely has complex interactions with post-COVID pulmonary measurements including MRI VDP. Importantly, there were no significant
differences for SGRQ and IPAQ scores between participants with and without a previous diagnosis of obstructive lung disease, which underscores the severity of illness in PACS. Finally, as previously reported, older people are at greater risk for poor COVID-19 outcomes and there is also a complex relationship between age and MRI VDP, so age must be considered as an important factor in our results. It should also be noted that the ever-COVID group was significantly older compared with never-COVID and hence this may have influenced VDP measurements in this group. However, MRI VDP was still greater in the ever-COVID group than predicted based on age alone. In conclusion, we explored a potential role for MRI and CT pulmonary pathologies to help explain persistent and life-altering symptoms including exercise limitation in post-COVID patients. While mean SGRQ score was not normal in the PACS participants studied here, spirometry, DLCO and CT measurements were normal or nearly normal. This provides some context to the growing body of evidence that shows MRI VDP provides a sensitive measure of abnormal physiology that, in the PACS participants studied here, may contribute to exercise limitation.

In this study, participants were unable to achieve pre-COVID work and day-to-day life activities, so we asked the question, is there an airways component to PACS that can be measured using MRI VDP and does this relate to quality-of-life? Yes, this exploratory study did point to a relationship between the lung pathologies that resulted in abnormal MRI VDP (or ventilation heterogeneity) as well as exercise limitation and abnormal post-exertional SpO2. SGRQ and IPAQ scores also were highly abnormal and very similar among ever-COVID participants. The study results point to a possible airways disease explanation for the persistent symptoms experienced following COVID-19 infection, which may help improve and target treatment.

**Contributors**  
HKK, MJM, AMM, CV, NR, NBK and SS were responsible for data acquisition. HKK and MJM were responsible for data analysis and for preparing the first draft of the manuscript. EAH and MA assisted with CT acquisition and evaluated the CT data. CV, TH, ID, JN and PN were responsible for recruiting study participants and providing clinical input and interpretation of the data. GES, MSA, AO and MK supported the study design and development and interpretation of the data. GP was responsible for study design, data analysis and interpretation as well as being the guarantor of study data integrity. All authors had an opportunity to review and revise the manuscript and approved its final submitted version.

**Funding**  
This study was funded by the Ministry of Health and Long-Term Care Ontario. AMM is supported by a Natural Sciences and Engineering Council (Canada) doctoral scholarship. GP, MK and SS are supported by the Canada Research Chair Program. Other contributions: The authors acknowledge the support of the London Health Sciences Centre COVID-19 clinic and Middlesex London Health Unit (which provided all COVID-19 testing and reporting), along with the participants who consented to this 2-year longitudinal study. David Reese, Carol Awde, Shannon Fasuruk and Julie Lecomte performed MRI. Angela Wilson, Chynna Huang and Melanie Kjarsgaard were responsible for pulmonary function testing.

**Competing interests**  
The authors have reported to BMJ Open Respiratory Research the following: TH has received grants from Fisher & Paykel, honoraria for speaking engagements from AstraZeneca, and has participated on advisory boards for Sanofi, AstraZeneca and Valeo, outside the submitted work. JN has received honoraria for speaking engagements from AstraZeneca, Horizon Therapeutics and Vertex, outside the submitted work. PN has received grants from AstraZeneca, Teva, Sanofi, Foresee and Cyclomedica and personal fees from AstraZeneca, Teva, Equilibrium, Arrowhead Pharma and GiaxoSmithKline, outside the submitted work. SS has received grants from Cyclomedica, personal fees from Arrowhead Pharma and honoraria for speaking engagements from AstraZeneca, Novartis and Polarean, outside the submitted work. GP has received grants from AstraZeneca and Novartis and honoraria for speaking engagements from AstraZeneca, outside the submitted work. GES, MSA, AO, MK, SS and GP received grants from the Ministry of Health and Long-Term Care Ontario related to this work. HKK, MJM, AMM, CV, NR, EAH, NBK, MA and ID have no conflicts to declare.

**Patient and public involvement**  
Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication**  
Not applicable.

**Ethics approval**  
This study involves human participants and was approved by HSREB #113224 and HiREB #12672. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review**  
Not commissioned; externally peer reviewed.

**Data availability statement**  
Data are available upon reasonable request.

**Supplemental material**  
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**  
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID ids**  
Alexei Ouriadov http://orcid.org/0000-0002-0920-2528  
Michael Nicholas http://orcid.org/0000-0003-1560-7967  
Grace Parraga http://orcid.org/0000-0002-5619-4145

**REFERENCES**  
1. Jennings G, Monaghan A, Xue F, et al. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. Post-COVID-19 syndrome. *J Clin Med* 2021;10:5913.  
2. Chopra V, Flanders SA, O’Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. *Ann Intern Med* 2021;174:576–8.
pulmonary ventilation: visualization at hyperpolarized He-nuclei MR imaging in asthma and COPD. Am J Respir Crit Care Med 2021;301:E396–405.

COVID-19 and implications for follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;298:E177–86.

Eddy RL, Svenningsen S, Kirby M, et al. Is computed tomography airway count related to asthma severity and airway structure and function? Am J Respir Crit Care Med 2020;201:923–33.

Eddy RL, Westcott A, Maksym GN, et al. Oscillography and pulmonary function imaging in asthma and COPD. Physiol Rep 2019;7:e13955.

Kauczor HU, Hofmann D, Kreitner KF, et al. Normal and abnormal pulmonary ventilation: visualization at hyperpolarized He-3 MR imaging. Radiology 1996;201:564–8.

Grist JT, Chelala J, Coller GJ, et al. Hyperpolarized 129Xe MRI Abnormalities in Dyspneic Patients 3 Months after COVID-19 Pneumonia: Preliminary Results. Radiology 2021;301:E353–60.

Li H, Zhao X, Wang Y, et al. Damaged lung gas exchange function of discharged COVID-19 patients detected by hyperpolarized 129Xe MRI. Sci Adv 2021;7:eabc1800. [Epub ahead of print: 01 01 2021].

Svenningsen S, Eddy RL, Lim HF, et al. Sputum eosinophilia and magnetic resonance imaging ventilation heterogeneity in severe asthma. Am J Respir Crit Care Med 2018;197:876–84.

Costella S, Kirby M, Maksym GN, et al. Regional pulmonary response to a methacholine challenge using hyperpolarized 3 He magnetic resonance imaging. Respir Med 2012;17:1237–46.

de Lange EE, Attes TA, Patrie JT, et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 2006;130:1055–62.

Mummary DG, Kruger SJ, Zha W, et al. Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma. J Allergy Clin Immunol 2018;141:1140–1.

Svenningsen S, Nair P, Guo F, et al. Is ventilation heterogeneity related to asthma control? Eur Respir J 2016;48:370–9.

Kirby M, Kanhere N, Etemad-Rezaei R, et al. Hyperpolarized helium-3 magnetic resonance imaging of chronic obstructive pulmonary disease exacerbation. J Magn Reson Imaging 2013;37:1223–39.

Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis 1992;145:1321–7.

Mahler DA, Ward J, Fiero-Carron G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 2004;1:165–72.

29 Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81.

30 Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381–95.

31 Cartwright PL. The six-minute walk test. Respir Care 2003;48:783–5.

32 Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38.

33 Robinson PD, Latzin P, Verbanck S, et al. Consensus statement for inert gas washout measurement using multiple- and single-breath techniques. Eur Respir J 2011;37:1121–31.

34 Macintyre N, Crapo RO, Viegli G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35.

35 Kirby M, Svenningsen S, Owanggi A, et al. Hyperpolarized 3He and 129Xe MRI imaging in patients with chronic obstructive pulmonary disease. Radiology 2012;265:800–10.

36 Farag A, Wang J, Urradov A. Unshielded and asymmetric RF transmit coil for hyperpolarized 3He human lung imaging at 3.0 T. Proc Intl Soc Mag Reson Med 2012;20:1233.

37 Walker TG, Happer W. Spin-exchange optical pumping of noble-gas nuclei. Rev Mod Phys 1997;69:629–42.

38 Kirby M, Pike D, McCormack DG, et al. Longitudinal computed tomography and magnetic resonance imaging of COPD: thoracic D.I.Y. imaging network of Canada (TINCan) study objectives. Chronic Obstr Pulm Dis 2014;1:200–11.

39 Kirby M, Heydarian M, Svenningsen S, et al. Hyperpolarized 3He magnetic resonance functional imaging semi-automated segmentation. Acad Radiol 2012;19:141–52.

40 Kirby M, Wheatley A, McCormack DG. Development and application of methods to quantify spatial and temporal hyperpolarized He-3 MRI ventilation dynamics: preliminary results in chronic obstructive pulmonary disease. Proc SPIE 2010;7626:762605.

41 Pike D, Kirby M, Guo F, et al. Ventilation heterogeneity in ex-smokers without airflow limitation. Acad Radiol 2015;22:1068–78.

42 Svenningsen S, Kirby M, Starr D, et al. Hyperpolarized 3He and 129Xe MRI: differences in asthma before bronchodilatation. J Magn Reson Imaging 2013;38:1521–30.

43 Nilm A, Matsumoto H, Aritani R, et al. Airway wall thickness in asthma evaluated by hyperpolarized 129Xe MRI. Eur Respir J 2013;41:507–22.

44 Matheson AM, Cunningham RSP, Bier E, et al. Hyperpolarized 129Xe Pulmonary MRI and Asymptomatic Atrial Septal Defect. Chest 2022;161:e199–202.

45 Ferrer M, Villasante C, Alonso J, et al. Interpretation of quality of life scores from the St George’s respiratory questionnaire. Eur Respir J 2002;19:405–13.

46 Horsley AR, Gustafsson PM, Macleod KA, et al. Lung clearance index is a sensitive, repeatable and practical measure of Airways Inflammatory Fibroblastic Fibrosis in adults with severe chronic obstructive pulmonary disease. Thorax 2008;63:135–40.

47 Anastasio F, Barbuto S, Scarnecchia E, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J 2021;58:200415.

48 Guler SA, Ebner L, Aubry-Romer C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the National prospective observational Swiss COVID-19 lung study. Eur Respir J 2021;57:2003690.

49 Wong AW, López-Romero S, Figueroa-Hurtado E, et al. Predictors of reduced 6-minute walk distance after COVID-19: a cohort study in Mexico. Pulmonology 2021;27:563–5.

50 Inui S, Yoon SH, Doganay O, et al. Impaired pulmonary ventilation beyond pneumonia in COVID-19: a preliminary observation. PLoS One 2022;17:e0283153.

51 Cho JL, Villacreses R, Jhappal P, et al. Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Radiology 2022;221:21170.

52 Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6:Suppl. 165–40.

53 Yanez ND, Weiss NS, Romand JA, et al. COVID-19 mortality risk for older men and women. BMC Public Health 2020;20:1742.

54 Parraga G, Mathew L, Etemad-Rezaei R, et al. Hyperpolarized 3He magnetic resonance imaging of ventilation defects in healthy elderly volunteers: initial findings at 3.0 Tesla. Acad Radiol 2008;15:776–85.

55 Sheikh K, Paulin GA, Svenningsen S, et al. Pulmonary ventilation defects in older never-smokers. J Appl Physiol 2014;117:297–306.
129Xe MRI Ventilation Defects in ever- and never- hospitalised people with post-acute COVID-19 Syndrome

Supplemental Materials
Table S1. Demographic Characteristics by Site

| Parameter mean (SD)                      | Never-COVID (n=9) | Ever-COVID (n=76) |
|------------------------------------------|------------------|-------------------|
|                                          | Site 1 (n=6)     | Site 2 (n=3)     | Site 1 (n=54) | Site 2 (n=22) | Sig. p       | Site 1 (n=54) | Site 2 (n=22) | Sig. p       |
| Age years                                | 35 (14)          | 37 (6)           | 54 (13)       | 50 (11)       | .8 0.2       | 54 (13)       | 50 (11)       | .2           |
| Female n (%)                             | 3 (50)           | 2 (67)           | 27 (50)       | 11 (50)       | .6 0.9       | 27 (50)       | 11 (50)       | .9           |
| BMI kg/m²                                | 25 (3)           | 28 (9)           | 30 (5)        | 29 (6)        | .8 0.2       | 30 (5)        | 29 (6)        | .2           |
| SpO₂ %                                   | 97 (2)           | ND               | 97 (2)        | 98 (2)        | .01          | 97 (2)        | 98 (2)        | .01          |
| Heart rate beats/ min                    | 87 (20)          | ND               | 77 (13)       | 78 (14)       | 1.0          | 77 (13)       | 78 (14)       | 1.0          |
| Blood pressure mmHg                      | 119/18 (79/12)   | ND               | 124/83 (13/10)| 126/79 (16/10)| -            | 124/83 (13/10)| 126/79 (16/10)| -            |
| Weeks Since + COVID Test                 | N/A              | N/A              | [15/12: 5-53] | [10/9: 5-18]  | .01          | [15/12: 5-53] | [10/9: 5-18]  | .01          |
| Smoking history pack-years               | 0 (0)            | 0 (0)            | 7 (15)        | 11 (23)       | .4           | 7 (15)        | 11 (23)       | .4           |
| No Prior Respiratory Illness n (%)       | 0 (0)            | 0 (0)            | 35 (65)       | 15 (64)       | .9           | 35 (65)       | 15 (64)       | .9           |
| Prior Respiratory Illness n (%)          | 0 (0)            | 0 (0)            | 19 (35)       | 8 (36)        | .9           | 19 (35)       | 8 (36)        | .9           |
| Asthma n (%)                             | 0 (0)            | 0 (0)            | 15 (28)       | 6 (27)        | 1.0          | 15 (28)       | 6 (27)        | 1.0          |
| COPD n (%)                               | 0 (0)            | 0 (0)            | 4 (7)         | 2 (9)         | .8           | 4 (7)         | 2 (9)         | .8           |
| Ever-hospitalised n (%)                  | N/A              | N/A              | 18 (33)       | 5 (23)        | .4           | 18 (33)       | 5 (23)        | .4           |
| Hospital Admission days                  | N/A              | N/A              | 14 (18)       | 9 (4)         | .5           | 14 (18)       | 9 (4)         | .5           |

BMI=body mass index; ND=not done; COPD=chronic obstructive pulmonary disease.

p=significance value between Site 1 and Site 2.
Table S2. Patient Listing of Medications at Research Visit

| Participant | Medications |
|-------------|-------------|
| P01         | Symbicort; Salbutamol; Spiriva; Fluticasone; Warfarin; Rosuvastatin; Metoprolol; Spironolactone; Dapagliflozin/Metformin; Sitagliptin; Lorazepam |
| P02         | None |
| P03         | Indapamide; Gliclazide; Empagliflozin; Atorvastatin; Metformin; Sitagliptin; Tamsulosin; Ranitidine; Levothyroxine; Bisoprolol |
| P04         | Insulin; Pregabalin; Gliclazide; Perindopril; Rosuvastatin; Sitagliptin/Metformin; Empagliflozin; Ezetimibe |
| P05         | Formoterol-mometasone |
| P06         | Pantoprazole; Apixaban |
| P07         | Levothyroxine |
| P08         | Levothyroxine; Symbicort; Trimethoprim and sulfamethoxazole |
| P09         | Symbicort; Amitriptyline; Naproxen; Pregabalin; Rosuvastatin; Sertraline |
| P10         | Salbutamol |
| P11         | Olanzapine; Fluoxetine; Quetiapine; Salbutamol |
| P12         | Symbicort |
| P13         | None |
| P14         | Fluticasone propionate-salmeterol; Salbutamol; Desvenlafaxine; Pantoprazole; Aripiprazole |
| P15         | None |
| P16         | Symbicort; Atenolol; Hydrochlorothiazide; Candesartan |
| P17         | Metformin; Rosuvastatin; Amlodipine; Ramipril; Hydrochlorothiazide |
| P18         | Metformin; Irbesartan; Esomeprazole; Tramadol; Azythromycin; Dexamethasone |
| P19         | Rivaroxaban; Levothyroxine; Oral Contraceptive |
| P20         | Symbicort; Singulair; Tresiba; Jardiance; Ezetrol; Insulin; Rivaroxaban; Glumetza; Pravastatin; Colchicine; Pantaprazole |
| P21         | Pregabalin |
| P22         | Perindopril; Pantoprazole; Rosuvastatin; Spiriva; Ezetimibe; Amlodipine; Bimatropost; Salbutamol; Epipen |
| P23         | Metformin; Symbicort |
| P24         | None |
| P25         | None |
| P26         | Gabapentin; Canagiflozin; Levothyroxine; Saxagliptin; Dexamethasone; Rosuvastatin; Metformin; Symbicort |
| P27         | Ustekinumab; Symbicort; Salbutamol |
| P28         | Nabilone; Venlafaxine; Ferrous Gluconate; Dexamethasone; Rosuvastatin; Levothyroxine; Gabapentin |
| P29         | Trazodone; Bupropion |
| P30         | Symbicort |
| P31         | None |
| P32         | Cetirizine; Trazadone; Rizatriptan; Betahistine |
| P33         | Fluticasone propionate-salmeterol; Salbutamol; Statin; Diuretic |
| P34         | Sitagliptin; Gliclazide; Ramipril; Atorvastatin; Symbicort |
| P35         | Anti-hypertension; Symbicort |
| P36         | Furosemide; Ciclesonide; Lorazepam; Tamsulosin; Lamotrigine; Spiriva Respimat; Atorvastatin; Symbicort; Ferrous Gluconate; Apixaban; Flecainide; Salbutamol |
| P37         | Triptans |
| P38         | None |
| P39         | Symbicort |
| P40         | None |
| P41         | Symbicort; Ipratropium bromide; Beclomethasone Nasal Spray |
| P42         | Symbicort; Perindopril; Amlodiprine |
| Page | Medications                                      |
|------|-------------------------------------------------|
| P43  | Symbicort                                       |
| P44  | Methylphenidate                                  |
| P45  | Furosemide; Ferrous fumarate; Candesartan; Rivaroxaban; Levothyroxine |
| P46  | Tansulosin; Bisoprolol; Ferrous fumarate; Apixaban; Rosuvastatin; Amlodipine; Finasteride; Fluticasone |
| P47  | Bupropion                                       |
| P48  | None                                            |
| P49  | Amitriptyline                                   |
| P50  | None                                            |
| P51  | Bupropion                                       |
| P52  | Formoterol-mometasone; Montelukast; Spiriva; Pantoprazole |
| P53  | Formoterol-mometasone; Salbutamol               |
| P54  | None                                            |
| P55  | Losartan, Clortalidone                          |
| P56  | Risedronic acid                                  |
| P57  | Candesartan, Rosuvastatin, Metformin             |
| P58  | Gabapentin, Amitriptyline, Clonazepam, Progesterone, Estradiol |
| P59  | Methylphenidate, Vortioxetine                   |
| P60  | None                                            |
| P61  | Spiriva, Symbicort                              |
| P62  | None                                            |
| P63  | Gliclazide, Duloxetine, Advair, Semaglutide, Ipratropium bromide, Salbutamol, Pantoprazole, Ciclesonide, Spiriva, Atorvastatin, Metformin, Acetaminophen-codeine-caffeine |
| P64  | Conjugated estrogens, Oxybutynin, Pantoprazole, Vortioxetine |
| P65  | Perindopril                                     |
| P66  | Salbutamol                                      |
| P67  | Bisoprolol, Bupropion, Metoclopramide            |
| P68  | Fluticasone furoate, Salbutamol, Carbamazepine  |
| P69  | Formoterol-mometasone, Ferrous fumarate          |
| P70  | Rupatadine, Mometasone, Montelukast, Oral Contraceptive |
| P71  | Fluticasone propionate                           |
| P72  | Telmisartan, Bisoprolol, Thyroxine, Pantoprazole |
| P73  | Metoprolol, Ramipril, Amlodipine, Metformin, Sitagliptin, Gliclazide, Rosuvastatin |
| P74  | Levothyroxine, Rabeprazole, Beclometasone, Tiotropium, Salbutamol |
| P75  | Ramipril, Budesonide, Lansoprazole, Symbicort, Rosuvastatin, Bisoprolol, Spiriva |
| P76  | Fluticasone salmeterol, Spiriva, Fluticasone propionate, Benralizumab |
| Parameter            | Ever-COVID (n=76) | Ever-hospitalised (n=23) | Never-hospitalised (n=53) |
|----------------------|-------------------|--------------------------|--------------------------|
| None                 | 13 (17)           | 2 (9)                    | 11 (21)                  |
| SABA                 | 10 (13)           | 4 (17)                   | 6 (11)                   |
| ICS                  | 34 (45)           | 12 (52)                  | 22 (42)                  |
| LABA                 | 30 (39)           | 10 (43)                  | 20 (38)                  |
| Anticoagulant        | 5 (7)             | 2 (9)                    | 3 (6)                    |
| Antibiotic           | 2 (3)             | 2 (9)                    | 0 (0)                    |
| Other                | 52 (68)           | 18 (78)                  | 34 (64)                  |

SABA=short-acting beta-agonist; ICS=inhaled corticosteroid; LABA=long-acting beta-agonist
| Abnormality                 | Ever-COVID (n=50) | No Prior Lung Diagnosis COVID (n=34) | Asthma-COVID (n=13) | COPD-COVID (n=3) |
|-----------------------------|-------------------|-------------------------------------|---------------------|------------------|
| Ground-Glass Opacities      | 20 (40)           | 14 (41)                             | 5 (38)              | 1 (33)           |
| Consolidation               | 4 (8)             | 2 (6)                               | 1 (8)               | 1 (33)           |
| Reticulation                | 2 (4)             | 2 (6)                               | 0 (0)               | 0 (0)            |
| Atelectasis                 | 14 (28)           | 10 (29)                             | 4 (31)              | 0 (0)            |
| Emphysema                   | 5 (10)            | 1 (3)                               | 2 (15)              | 2 (67)           |
| Honeycombing                | 1 (2)             | 1 (3)                               | 0 (0)               | 0 (0)            |
| Mosaic Attenuation          | 4 (8)             | 3 (9)                               | 1 (8)               | 0 (0)            |
| Bronchial Wall Thickening   | 1 (2)             | 1 (3)                               | 0 (0)               | 0 (0)            |
| Nodules                     | 13 (26)           | 8 (24)                              | 5 (38)              | 0 (0)            |
| Bronchiectasis              | 11 (22)           | 8 (24)                              | 3 (23)              | 0 (0)            |
| Bronchiolextasia            | 1 (2)             | 1 (3)                               | 0 (0)               | 0 (0)            |
### Table S5. Pulmonary Function, Questionnaire and Imaging Measurements by Site

| Parameter                      | Never-COVID (n=9) | Ever-COVID (n=76) | Site 1 | Site 2 | Sig. p | Site 1 | Site 2 | Sig. p |
|-------------------------------|-------------------|-------------------|--------|--------|--------|--------|--------|--------|
| **Pulmonary function**        |                   |                   |        |        |        |        |        |        |
| FEV<sub>1</sub> * % <sub>pred</sub> | 100 (7)           | 103 (17)          | .7     | 86 (20) | 81 (20) | .4     |
| FVC* % <sub>pred</sub>        | 102 (7)           | 104 (16)          | .9     | 87 (18) | 92 (24) | .3     |
| FEV<sub>1</sub>/FVC*          | 0.80 (0.05)       | 0.84 (0.04)       | .3     | 0.77 (0.11) | 0.74 (0.11) | .2     |
| LCI* n breaths               | 9.0 (1.4)         | ND                | 10.7 (3.9) | ND | - | - |
| LCI<sub>ao</sub>* n breaths  | 8.0 (1.3)         | ND                | 9.5 (3.3) | ND | - | - |
| DL<sub>CO</sub>* % <sub>pred</sub> | -                 | -                 | -     | 81 (21) | 105 (35) | .007 |
| **Exercise capacity and QoL** |                   |                   |        |        |        |        |        |        |
| 6MWD* m                       | -                 | -                 | 435 (79) | 491 (80) | .008 |
| SpO<sub>2</sub> post-exertion* % | -                 | -                 | 97 (3) | 99 (2) | .01 |
| SGRQ*                         | -                 | -                 | 34 (17) | 38 (19) | .4 |
| mMRC*                         | -                 | -                 | 1 (1) | 1 (1) | 3 |
| IPAQ* MET-minutes             | -                 | -                 | 4276 (4651) | 5778 (5451) | .3 |
| **MRI**                       |                   |                   |        |        |        |        |        |        |
| VDP %                         | 1.4 (1.0)         | 0.5 (0.3)         | .2     | 6.2 (7.9) | 3.6 (4.3) | .2     |
| **CT**                        |                   |                   |        |        |        |        |        |        |
| TAC                           | -                 | -                 | 270 (104) | 267 (139) | .9 |
| WA mm<sup>2</sup>             | -                 | -                 | 66 (2) | 67 (3) | .4 |
| LA mm<sup>2</sup>             | -                 | -                 | 14 (3) | 12 (3) | .2 |
| WT mm                         | -                 | -                 | 1.4 (0.1) | 1.3 (0.1) | .2 |

FEV<sub>1</sub>* FVC* and FEV<sub>1</sub>/FVC*: Ever-COVID Site 1 n=53
LCI*: Never-COVID n=5, Ever-COVID Site 1 n=44
LCI<sub>ao</sub>*: Never-COVID n=5, Ever-COVID Site 1 n=32
DL<sub>CO</sub>*: Ever-COVID Site 1 n=43, Ever-COVID Site 2 n=21
6MWD* and mMRC*: Ever-COVID Site 1 n=43
SpO<sub>2</sub> post-exertion*: Ever-COVID Site 1 n=43
SGRQ*: Ever-COVID Site 1 n=44, Ever-COVID Site 2 n=20
IPAQ*: Ever-COVID Site 1 n=42, Ever-COVID Site 2 n=17
CT*: Ever-COVID Site 1 n=36, Ever-COVID Site 2 n=8

FEV<sub>1</sub>= forced expiratory volume in 1 second; %<sub>pred</sub>=percent of predicted value; FVC=forced vital capacity; LCI=lung clearance index; ND=not done; ao=airway opening; DL<sub>CO</sub>=diffusing capacity of the lungs for carbon monoxide; QoL=quality-of-life; 6MWD=six-minute walk distance; SGRQ=St. George’s Respiratory Questionnaire; mMRC=modified Medical Research Council dyspnea score; IPAQ=International Physical Activity Questionnaire; MRI=magnetic resonance imaging; VDP=ventilation defect percent; CT=computed tomography; TAC=total airway count; WA=wall area; LA=lumen area; WT=wall thickness.

*Significance value between Site 1 and Site 2.

FEV<sub>1</sub>* FVC* and FEV<sub>1</sub>/FVC*: Ever-COVID Site 1 n=53
LCI*: Never-COVID n=5, Ever-COVID Site 1 n=44
LCI<sub>ao</sub>*: Never-COVID n=5, Ever-COVID Site 1 n=32
DL<sub>CO</sub>*: Ever-COVID Site 1 n=43, Ever-COVID Site 2 n=21
6MWD* and mMRC*: Ever-COVID Site 1 n=43
SpO<sub>2</sub> post-exertion*: Ever-COVID Site 1 n=43
SGRQ*: Ever-COVID Site 1 n=44, Ever-COVID Site 2 n=20
IPAQ*: Ever-COVID Site 1 n=42, Ever-COVID Site 2 n=17
CT*: Ever-COVID Site 1 n=36, Ever-COVID Site 2 n=8

Kooner HK, et al. BMJ Open Resp Res 2022; 9:e001235. doi: 10.1136/bmjresp-2022-001235
### Table S6. Characteristics by Previous Lung disease

| Parameter                  | No Prior Lung Diagnosis COVID (n=49) | Asthma-COVID (n=21) | COPD-COVID (n=6) | Sig. p |
|----------------------------|-------------------------------------|---------------------|-----------------|--------|
| [mean/MEDIAN: min-max]     |                                     |                     |                 |        |
| Age years                  | 52 (12)                             | 55 (13)             | 59 (11)         | .3     |
| Female n (%)               | 23 (47)                             | 14 (67)             | 1 (17)          | -      |
| BMI kg/m²                  | 30 (5)                              | 28 (6)              | 30 (4)          | .4     |
| SpO₂ %                     | 97 (1)                              | 97 (2)              | 96 (2)          | .1     |
| Heart rate beats/min       | 78 (13)                             | 75 (14)             | 79 (8)          | .6     |
| Blood pressure mmHg        | 126/82 (15/10)                      | 124/81 (13/9)       | 120/78 (13/13)  | -      |
| Weeks Since + COVID Test   | [14/12: 5-53]                       | [13/12: 6-29]       | [13/13: 6-20]   | .8     |
| Smoking history pack-years | 4 (11)                              | 5 (10)              | 50 (27)         | <.001  |
| Ever-hospitalised n (%)    | 18 (37)                             | 5 (24)              | 2 (33)          | -      |
| Hospital Admission days    | 14 (18)                             | 8 (6)               | 7 (1)           | -      |

#### Pulmonary function

| Parameter                  | No Prior Lung Diagnosis COVID (n=49) | Asthma-COVID (n=21) | COPD-COVID (n=6) | Sig. p |
|----------------------------|-------------------------------------|---------------------|-----------------|--------|
| FEV₁* %pred                | 87 (18)                             | 82 (24)             | 74 (24)         | .3     |
| FVC* %pred                 | 88 (19)                             | 85 (21)             | 96 (19)         | .1     |
| FEV₁/FVC*                  | 0.79 (0.08)                         | 0.75 (0.12)         | 0.60 (0.16)     | <.001  |
| LCI* n breaths             | 11.1 (3.9)                          | 9.9 (4.1)           | 10.4 (2.5)      | .7     |
| LCIao* n breaths           | 9.3 (3.3)                           | 10.0 (3.6)          | 8.4             | .8     |
| DLCO* %pred                | 90 (33)                             | 88 (19)             | 77 (16)         | .6     |

#### Exercise capacity and QoL

| Parameter                  | No Prior Lung Diagnosis COVID (n=49) | Asthma-COVID (n=21) | COPD-COVID (n=6) | Sig. p |
|----------------------------|-------------------------------------|---------------------|-----------------|--------|
| 6MWD* m                    | 468 (74)                            | 445 (81)            | 382 (127)       | .05    |
| SpO₂ post-exertion* %      | 97 (3)                              | 98 (2)              | 96 (4)          | .6     |
| SGRQ*                      | 34 (16)                             | 38 (21)             | 25 (21)         | .7     |
| mMRC*                      | 1 (1)                               | 1 (1)               | 1 (1)           | .7     |
| IPAQ* MET-minutes          | 5286 (5448)                         | 3577 (3727)         | 3060 (1767)     | .5     |
| VDP %                      | 3.6 (4.2)                           | 6.7 (7.6)           | 15.8 (14.1)     | <.001  |
| CT*                        | 294 (117)                           | 241 (76)            | 126 (61)        | .06    |
| WA mm²                     | 66 (2)                              | 67 (2)              | 68 (2)          | .08    |
| LA mm²                     | 15 (3)                              | 12 (3)              | 11 (1)          | .09    |
| WT mm                      | 1.4 (0.1)                           | 1.3 (0.1)           | 1.3 (0.02)      | .04    |

COPD=chronic obstructive pulmonary disease; BMI=body mass index; FEV₁=forced expiratory volume in 1 second; %pred=percent of predicted value; FVC=forced vital capacity; LCI=diffusing capacity of the lungs for carbon monoxide; QoL=quality-of-life; 6MWD=six-minute walk distance; SGRQ=St. George’s Respiratory Questionnaire; mMRC=modified Medical Research Council dyspnea score; IPAQ=International Physical Activity Questionnaire; MRI=magnetic resonance imaging; VDP=ventilation defect percent; CT=computed tomography; TAC=total airway count; WA=wall area; LA=lumen area; WT=wall thickness.
p=significance value for ANOVA.

FEV₁*, FVC* and FEV₁/FVC*: Asthma-COVID n=20

LCl*: No Prior Lung Diagnosis COVID n=29, Asthma-COVID n=12, COPD-COVID n=3

LClao*: No Prior Lung Diagnosis COVID n=22, Asthma-COVID n=4, COPD-COVID n=1

DLCO*: No Prior Lung Diagnosis COVID n=43, Asthma-COVID n=16, COPD-COVID n=5

6MWD* and mMRC*: No Prior Lung Diagnosis COVID n=42, Asthma-COVID n=18

SpO₂ post-exertion*: No Prior Lung Diagnosis COVID n=42, Asthma-COVID n=17

SGRQ*: No Prior Lung Diagnosis COVID n=42, Asthma-COVID n=17

IPAQ*: No Prior Lung Diagnosis COVID n=38, Asthma-COVID n=18, COPD-COVID n=3
CT*: No Prior Lung Diagnosis COVID n=28, Asthma-COVID n=14, COPD-COVID n=2
Table S7. Relationships between pulmonary function tests, imaging and quality-of-life measurements

| Test 1   | Test 2   | r/ρ | p    | r/ρ  | p    |
|----------|----------|-----|------|-----|------|
| FEV1     | FVC      | .3  | .01  | .3  | .01  |
| FVC      | FEV1     | -.3 | .003 | -.4 | .002 |
| DLco TLC | DLco TLC | -.05| .02  | -.3 | .001 |
| DLco TLC | FEV1     | -.2 | .003 | -.4 | .002 |
| DLco TLC | FVC      | -.2 | .003 | -.4 | .002 |
| VDP      | FVC      | -1.0| 1.0  | -1.0| 1.0  |
| VDP      | FEV1     | -1.0| 1.0  | -1.0| 1.0  |
| VDP      | DLco TLC | -1.0| 1.0  | -1.0| 1.0  |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on the supplemental material which has been supplied by the authors.
**Figure S1.** $^{129}$Xe MRI VDP, pulmonary function, exercise capacity and quality-of-life by prior respiratory illness

VDP significantly different for COPD-COVID vs. no prior lung diagnosis COVID (p<.001) and asthma-COVID (p=.002). 6MWD significantly different for no prior lung diagnosis COVID vs. COPD-COVID (p=.02). LCI, DL$_{CO}$, IPAQ and SGRQ not significantly different between groups.

*VDP=* ventilation defect percent; *LCI=* lung clearance index; *6MWD=* six-minute walk distance; *DL$_{CO}$=* diffusing capacity of the lungs; *%pred=* percent of predicted value; *IPAQ=* International Physical Activity Questionnaire; *SGRQ=* St. George’s Respiratory Questionnaire.
Figure S2. Abnormal VDP Subgroups

6MWD significantly worse in VDP≥4.3% than VDP<4.3% (p=.003)
SpO₂ post-exertion significantly worse in VDP≥4.3% than VDP<4.3% (p=.03)

6MWD=six-minute walk distance; VDP=ventilation defect percent